Cetera Investment Advisers Buys 196 Shares of STERIS plc $STE

Cetera Investment Advisers raised its stake in STERIS plc (NYSE:STE) by 2.8% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,195 shares of the medical equipment provider’s stock after purchasing an additional 196 shares during the period. Cetera Investment Advisers’ holdings in STERIS were worth $1,728,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of STE. Orbis Allan Gray Ltd bought a new stake in shares of STERIS in the first quarter valued at about $349,950,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in STERIS by 55.2% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,520,479 shares of the medical equipment provider’s stock valued at $344,617,000 after acquiring an additional 540,999 shares in the last quarter. Nuveen LLC bought a new stake in shares of STERIS in the 1st quarter worth approximately $65,435,000. Generation Investment Management LLP lifted its position in shares of STERIS by 5.4% in the 1st quarter. Generation Investment Management LLP now owns 3,354,545 shares of the medical equipment provider’s stock worth $760,308,000 after acquiring an additional 170,392 shares during the period. Finally, AQR Capital Management LLC grew its holdings in shares of STERIS by 507.2% during the 1st quarter. AQR Capital Management LLC now owns 184,150 shares of the medical equipment provider’s stock worth $41,115,000 after purchasing an additional 153,821 shares in the last quarter. 94.69% of the stock is currently owned by institutional investors and hedge funds.

STERIS Stock Down 0.2%

Shares of NYSE STE opened at $266.28 on Monday. STERIS plc has a 52-week low of $200.98 and a 52-week high of $268.60. The company has a debt-to-equity ratio of 0.27, a quick ratio of 1.53 and a current ratio of 2.22. The business has a fifty day moving average of $248.65 and a two-hundred day moving average of $242.98. The stock has a market cap of $26.13 billion, a PE ratio of 40.78 and a beta of 1.02.

STERIS (NYSE:STE) last announced its earnings results on Wednesday, November 5th. The medical equipment provider reported $2.47 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.38 by $0.09. STERIS had a net margin of 11.61% and a return on equity of 14.17%. The business had revenue of $1.46 billion during the quarter, compared to analysts’ expectations of $1.43 billion. During the same quarter last year, the company posted $2.14 EPS. STERIS has set its FY 2026 guidance at 10.150-10.30 EPS. As a group, equities research analysts expect that STERIS plc will post 9.08 earnings per share for the current fiscal year.

STERIS Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 18th. Stockholders of record on Tuesday, November 18th will be paid a $0.63 dividend. The ex-dividend date is Tuesday, November 18th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 0.9%. STERIS’s payout ratio is 36.21%.

Insiders Place Their Bets

In other STERIS news, VP John Adam Zangerle sold 15,000 shares of STERIS stock in a transaction on Tuesday, November 11th. The stock was sold at an average price of $265.14, for a total value of $3,977,100.00. Following the completion of the transaction, the vice president owned 33,669 shares in the company, valued at approximately $8,926,998.66. The trade was a 30.82% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Renato Tamaro sold 5,036 shares of the business’s stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $257.55, for a total value of $1,297,021.80. Following the completion of the transaction, the vice president directly owned 5,695 shares in the company, valued at approximately $1,466,747.25. This represents a 46.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 25,203 shares of company stock valued at $6,624,667 over the last quarter. 1.07% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

STE has been the subject of a number of recent research reports. Morgan Stanley upped their target price on STERIS from $276.00 to $295.00 and gave the company an “overweight” rating in a research note on Friday, August 8th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of STERIS in a report on Tuesday, October 14th. Finally, Wall Street Zen raised shares of STERIS from a “buy” rating to a “strong-buy” rating in a research note on Sunday, September 14th. Seven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, STERIS currently has a consensus rating of “Moderate Buy” and a consensus price target of $273.50.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.